scholarly journals High expression levels of CLEC4M indicate poor prognosis in patients with hepatocellular carcinoma

2020 ◽  
Author(s):  
Liuping Luo ◽  
Lihong Chen ◽  
Kun Ke ◽  
Bixing Zhao ◽  
Lili Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Poor Prognosis ◽  
High Expression ◽  
Expression Levels

High expression levels of putative hepatic stem/progenitor cells biomarkers related to tumor angiogenesis and poor prognosis of hepatocellular carcinoma

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22121-e22121
Author(s):  
Y. Xu ◽  
J. Fan ◽  
X. Yang ◽  
J. Zhou ◽  
S. Qiu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Progenitor Cells ◽  
Tumor Angiogenesis ◽  
Poor Prognosis ◽  
High Expression ◽  
Simplified Model ◽  
Recurrence Time ◽  
Cytokeratin 19 ◽  
Expression Levels ◽  
Qrt Pcr

e22121 Background: To investigate the prognostic values of putative hepatic stem/progenitor cells (HSCs/HPCs) biomarkers in hepatocellular carcinoma (HCC) patients. Methods: Fourteen biomarkers related with HSCs/HPCs or tumor angiogenesis were assessed by qRT-PCR and then validated by tissue microarrays (TMAs) in three independent cohorts of HCC patients underwent curative resection (n=67, 314 and 73). Results: Most of the biomarkers were found over-expressed in recurrent HCC patients by qRT-PCR. HSCs/HPCs biomarkers cytokeratin 19, ABCG2, CD133, Nestin, CD44 and angiogenesis agents CD34, VEGF and PD-ECGF, were confirmed as significant predictors for overall survival (OS) and/or relapse-free survival (RFS) in TMAs analysis. Compared with the low HSCs/HPCs profile group, patients with high HSCs/HPCs profile had significantly lower OS and RFS (p<0.0001), expressed higher VEGF levels (p = 0.012) and microvessel density (MVD, determined by CD34 immunostaining, p = 0.030). Based on Cox regression, a simplified model including CD133, CD44, Nestin, and MVD was constructed and confirmed as an independent predictor for OS (p<0.0001) and RFS (p<0.0001), regardless of alpha-fetoprotein level, tumor stage and recurrence time (p<0.0001 for all). Conclusions: High expression levels of HSCs/HPCs biomarkers are related to tumor angiogenesis and poor prognosis of HCC. The simplified model based on HSCs/HPCs and tumor angiogenesis profile can be used to classify HCC patients with high risk of tumor recurrence after operation. No significant financial relationships to disclose.

scholarly journals High Expression of ANXA2 Pseudogene ANXA2P2 Promotes an Aggressive Phenotype in Hepatocellular Carcinoma

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Qiu-shuang Wang ◽  
Liang-Liang Shi ◽  
Fei Sun ◽  
Yi-fan Zhang ◽  
Ren-Wang Chen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Disease Free Survival ◽  
Annexin A2 ◽  
The Cancer Genome Atlas ◽  
High Expression ◽  
Migration And Invasion ◽  
Targeted Drugs ◽  
Noncancerous Tissue ◽  
Expression Levels ◽  
Hcc Cells

Objective. Accumulating evidence suggests that pseudogenes play potential roles in the regulation of their cognate wild-type genes, oncogenes, and tumor suppressor genes. ANXA2P2 (annexin A2 pseudogene 2) is one of three pseudogenes of annexin A2 that have recently been shown to be aberrantly transcribed in hepatocellular carcinoma (HCC) cells. However, its clinical meaning and biological function in HCC have remained unclear. Therefore, the present study was aimed at exploring the prognostic value of a high expression of ANXA2P2 in HCC tissue and at identifying whether it can affect the efficacy of targeted drugs (sorafenib, regorafenib, and lenvatinib). Methods. We obtained ANXA2P2 mRNA expression levels from The Cancer Genome Atlas (TCGA) RNA sequence database. The expression levels of ANXA2P2 in 49 pairs of intratumoral and peritumoral liver tissues were examined by RT-PCR. Wound healing and transwell assays were performed to confirm the tumor-promoting properties of ANXA2P2 in HCC cells. CCK8 assay was conducted to identify whether ANXA2P2 can affect the growth of HCC cells when administered with targeted drugs (sorafenib, regorafenib, and lenvatinib). Results. The expression of ANXA2P2 in HCC tissues was significantly higher than that in adjacent cancerous tissues from TCGA database and validation group. Additionally, patients with high ANXA2P2 expression in HCC tissue had a shorter overall survival, whereas no statistically significant correlation was found between ANXA2P2 expression and disease-free survival (p=0.08) as well as other clinical parameters, such as age, gender, histological grade, T classification, stage, albumin level, alpha-fetoprotein, and vascular invasion (p=0.7323, 0.8807, 0.5762, 0.8515, 0.7113, 0.242, 1.0000, and 0.7685, respectively). Furthermore, in vitro experiments showed that knockdown of ANXA2P2 inhibited migration and invasion of HCC cells but did not have an influence on the HCC cell proliferation when treated with targeted drugs (sorafenib, regorafenib, and lenvatinib). Conclusion. Our study confirmed elevated ANXA2P2 expression levels in HCC tissue compared with adjacent noncancerous tissue and a worse prognosis of patients with high ANXA2P2 levels in the HCC tissue. The newly found properties of promoting migration and invasion of ANXA2P2 in HCC help to explain this phenomenon. ANXA2P2 could be a novel and suitable predicative biomarker for the risk assessment of recurrence or metastasis of HCC patients but may not be effective to predict the efficacy of targeted drugs.

High expression of Anxa2 and Stat3 promote progression of hepatocellular carcinoma and predict poor prognosis

2019 ◽  
Vol 215 (6) ◽  
pp. 152386 ◽  
Author(s):  
Lei Tang ◽  
Jin-Xia Liu ◽  
Zi-Juan Zhang ◽  
Chen-Zhou Xu ◽  
Xue-Ning Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Poor Prognosis ◽  
High Expression

High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma

2012 ◽  
Vol 43 (9) ◽  
pp. 1425-1435 ◽  
Author(s):  
Chuanchao He ◽  
Junyao Xu ◽  
Jianlong Zhang ◽  
Dan Xie ◽  
Hua Ye ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Poor Prognosis ◽  
Histone H3 ◽  
High Expression

High Expression of CCL20 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma after Curative Resection

2011 ◽  
Vol 16 (4) ◽  
pp. 828-836 ◽  
Author(s):  
Xiangjiu Ding ◽  
Kexin Wang ◽  
Hui Wang ◽  
Guangyong Zhang ◽  
Yajing Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Poor Prognosis ◽  
Curative Resection ◽  
High Expression

scholarly journals High Expression of FLOT1 Is Associated with Progression and Poor Prognosis in Hepatocellular Carcinoma

PLoS ONE ◽  
2013 ◽  
Vol 8 (6) ◽  
pp. e64709 ◽  
Author(s):  
Shi-Hong Zhang ◽  
Chan-Juan Wang ◽  
Ling Shi ◽  
Xing-Hua Li ◽  
Jing Zhou ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Poor Prognosis ◽  
High Expression

scholarly journals High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy

2014 ◽  
Vol 12 (1) ◽  
pp. 226 ◽  
Author(s):  
Haoyuan Wang ◽  
Shanshan Jiang ◽  
Yaojun Zhang ◽  
Ke Pan ◽  
Jianchuan Xia ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Poor Prognosis ◽  
High Expression ◽  
Thymosin Beta 10
Sign in / Sign up

Export Citation Format

Share Document